Skip to content

Alcyone Therapeutics has been acquired by Biogen. Please visit www.biogen.com for more information.

About
Science & Technology
- Platforms
- Publications
Pipeline & Programs
- Pipeline
- EPH-101
- XGR-101
Investors & Media
- Investors
- Press Releases
Careers
Contact

Blog

Targeting microRNA-dependent control of X chromosome inactivation improves the Rett Syndrome phenotype | Nature Communications

©2026 Alcyone Therapeutics • Privacy • Terms of Use • Site Credits